Edition:
United States

Ascendis Pharma A/S (ASND.OQ)

ASND.OQ on NASDAQ Stock Exchange Global Select Market

60.00USD
12:49pm EST
Change (% chg)

$2.00 (+3.45%)
Prev Close
$58.00
Open
$60.99
Day's High
$62.99
Day's Low
$59.83
Volume
413,096
Avg. Vol
37,708
52-wk High
$62.99
52-wk Low
$21.95

Select another date:

Wed, Feb 21 2018

BRIEF-Ascendis Pharma prices 3.9 mln American Depositary Shares At $57 Per ADS

* ASCENDIS PHARMA A/S ANNOUNCES PRICING OF PUBLIC OFFERING OF ADSS

BRIEF-Ascendis Pharma A/S Announces Proposed Public Offering Of ADSS

* ASCENDIS PHARMA A/S ANNOUNCES PROPOSED PUBLIC OFFERING OF ADSS

BRIEF-Ascendis Pharma Says Completed Target Enrollment In Phase 3 Trial Of Pediatric Growth Hormone Deficiency Treatment

* ASCENDIS PHARMA ANNOUNCES COMPLETION OF TARGET ENROLLMENT IN PHASE 3 TRIAL OF TRANSCON GROWTH HORMONE FOR PEDIATRIC GROWTH HORMONE DEFICIENCY

BRIEF-Ascendis Pharma Initiates Submissions In Australia To Enter Study With Transcon CNP

* ASCENDIS PHARMA SAYS ON DEC 20, INITIATED REGULATORY SUBMISSIONS IN AUSTRALIA TO ENTER INTO FIRST HUMAN CLINICAL STUDY WITH TRANSCON CNP - SEC FILING Source text : (http://bit.ly/2BTTLso) Further company coverage:

BRIEF-Ascendis Pharma A/S Q3 loss per share EUR 1.04

* Ascendis Pharma A/S reports third quarter 2017 financial results

BRIEF-Ascendis Pharma A/S prices public offering of 3.8 mln shares at $35.50 per ADS

* Ascendis Pharma A/S announces pricing of public offering of ADSs

BRIEF-Ascendis Pharma A/S announces proposed public offering of ADSs

* Ascendis Pharma A/S announces proposed public offering of ADSs

BRIEF-Ascendis Pharma A/S reports dosing of subjects in phase 1 trial of transcon pth

* Ascendis Pharma A/S announces dosing of subjects in phase 1 trial of Transcon pth

Select another date: